Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T17:56:38.014Z Has data issue: false hasContentIssue false

1.—Nardil (Phenelzine) As a Potentiator of Electroconvulsive Therapy (E.C.T.)

2.—A Survey of Out-Patient E.C.T.

Published online by Cambridge University Press:  08 February 2018

David Muller*
Affiliation:
Park Prewett Group of Hospitals

Extract

The following are summaries of work carried out at Powick Hospital, Worcester, as a project approved by the Medical Research Committee of the Birmingham Regional Hospital Board, which also gave financial assistance.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Arnow, L. E., Clin. Med., 1959, 6, 1573.Google Scholar
2 King, P. D., “Phenelzine and E.C.T. in the Treatment of Depression”, Amer. J. Psychiatry, 1959, 116/1, 64.Google Scholar
3 Azima, H., “Imipramine (Tofranil)—A New Drug for the Depressed”, Canad. Med. Ass. J., 1959, 80, 535.Google Scholar
4 University of Cambridge, Symposium on Depression, 1959. Cambridge: University Press.Google Scholar
5 Sargant, W., “The Anti-depressant Drugs”, Brit. Med. J., 1961, i, 225.Google Scholar
6 Kothari, U. C., “Toxic and Other Side-Effects of Nardil”, Amer. J. Psychiat., 1960, 116, 746.Google Scholar
7 Ackner, B., and Grant, Q. A. F. R., “Prognostic Significance of Depersonalization in Depressive Illnesses treated with Electroconvulsive Therapy”, J. Neurol. Neurosurg. and Psychiat., 1960, 23, 242.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.